VKTX – Viking Therapeutics Inc.
Viking Therapeutics, Inc.VKTX
$29.23Name : Viking Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,393,767,680.00
EPSttm : -4.15
Viking Therapeutics, Inc.
$29.23
0.03%$0.01
VKTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
19.74
Margin Of Safety %
Put/Call OI Ratio
0.21
EPS Next Q Diff
0.27
EPS Last/This Y
-1.53
EPS This/Next Y
0.16
Price
29.23
Target Price
94.29
Analyst Recom
1.21
Performance Q
-15.67
Upside
-284.6%
Beta
0.72
Ticker: VKTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | VKTX | 31.74 | 0.19 | 0.10 | 180767 |
| 2026-05-12 | VKTX | 31.33 | 0.18 | 0.13 | 187065 |
| 2026-05-13 | VKTX | 31.71 | 0.18 | 0.60 | 187384 |
| 2026-05-14 | VKTX | 31.7 | 0.18 | 0.18 | 188507 |
| 2026-05-15 | VKTX | 30.27 | 0.18 | 0.53 | 189455 |
| 2026-05-18 | VKTX | 28.68 | 0.16 | 0.58 | 144675 |
| 2026-05-19 | VKTX | 28.4 | 0.22 | 0.05 | 162634 |
| 2026-05-20 | VKTX | 29.44 | 0.22 | 0.11 | 165066 |
| 2026-05-21 | VKTX | 30.68 | 0.21 | 0.30 | 168034 |
| 2026-05-22 | VKTX | 30.92 | 0.21 | 0.25 | 170468 |
| 2026-05-26 | VKTX | 30.82 | 0.22 | 0.13 | 157621 |
| 2026-05-27 | VKTX | 31.66 | 0.21 | 0.33 | 162733 |
| 2026-05-28 | VKTX | 32.19 | 0.22 | 0.21 | 167575 |
| 2026-05-29 | VKTX | 32.71 | 0.21 | 0.07 | 173154 |
| 2026-06-02 | VKTX | 29.26 | 0.21 | 0.41 | 170162 |
| 2026-06-03 | VKTX | 29.32 | 0.22 | 0.32 | 175744 |
| 2026-06-04 | VKTX | 29.76 | 0.22 | 0.20 | 176617 |
| 2026-06-05 | VKTX | 28.45 | 0.22 | 0.30 | 179377 |
| 2026-06-08 | VKTX | 29.26 | 0.21 | 0.11 | 169055 |
| 2026-06-09 | VKTX | 29.22 | 0.21 | 0.23 | 174293 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | VKTX | 31.72 | -112.1 | -106.1 | -4.73 |
| 2026-05-12 | VKTX | 31.31 | -112.1 | -87.4 | -4.73 |
| 2026-05-13 | VKTX | 31.72 | -112.1 | -106.5 | -4.73 |
| 2026-05-14 | VKTX | 31.69 | -112.1 | -96.8 | -4.73 |
| 2026-05-15 | VKTX | 30.27 | -112.1 | -63.4 | -4.73 |
| 2026-05-18 | VKTX | 28.68 | -112.1 | -57.7 | -4.73 |
| 2026-05-19 | VKTX | 28.40 | -112.1 | -89.7 | -4.73 |
| 2026-05-20 | VKTX | 29.43 | -112.1 | -124.7 | -4.73 |
| 2026-05-21 | VKTX | 30.67 | -112.1 | -128.6 | -4.73 |
| 2026-05-22 | VKTX | 30.90 | -112.1 | -102.5 | -4.73 |
| 2026-05-26 | VKTX | 30.81 | -112.1 | -95.1 | -4.73 |
| 2026-05-27 | VKTX | 31.65 | -112.1 | -117.7 | -4.73 |
| 2026-05-28 | VKTX | 32.17 | -112.1 | -108.9 | -4.73 |
| 2026-05-29 | VKTX | 32.72 | -112.1 | -109.5 | -4.73 |
| 2026-06-01 | VKTX | 31.27 | -100.0 | -64.0 | -4.72 |
| 2026-06-02 | VKTX | 29.32 | -100.0 | -51.2 | -4.72 |
| 2026-06-03 | VKTX | 29.34 | -100.0 | -98.4 | -4.72 |
| 2026-06-04 | VKTX | 29.79 | -100.0 | -108.4 | -4.72 |
| 2026-06-05 | VKTX | 28.45 | -100.0 | -63.5 | -4.72 |
| 2026-06-08 | VKTX | 29.25 | -100.0 | -118.4 | -4.72 |
| 2026-06-09 | VKTX | 29.23 | -100.0 | -96.7 | -4.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | VKTX | -9.94 | -1.33 | 20.48 |
| 2026-05-12 | VKTX | -9.94 | -1.33 | 20.07 |
| 2026-05-13 | VKTX | -9.94 | -1.33 | 20.07 |
| 2026-05-14 | VKTX | -9.94 | -1.33 | 20.07 |
| 2026-05-15 | VKTX | -9.94 | -1.33 | 20.07 |
| 2026-05-18 | VKTX | -9.94 | -1.96 | 20.07 |
| 2026-05-19 | VKTX | -9.98 | -1.96 | 20.07 |
| 2026-05-20 | VKTX | -9.98 | -1.96 | 20.07 |
| 2026-05-21 | VKTX | -9.98 | -1.96 | 20.07 |
| 2026-05-22 | VKTX | -9.98 | -1.96 | 20.07 |
| 2026-05-26 | VKTX | -9.98 | 1.07 | 20.07 |
| 2026-05-27 | VKTX | -9.98 | 1.07 | 20.07 |
| 2026-05-28 | VKTX | -9.98 | 1.07 | 19.74 |
| 2026-05-29 | VKTX | -9.98 | 1.07 | 19.74 |
| 2026-06-02 | VKTX | -9.98 | 0.30 | 19.74 |
| 2026-06-03 | VKTX | -9.98 | 0.30 | 19.74 |
| 2026-06-04 | VKTX | -9.98 | 0.30 | 19.74 |
| 2026-06-05 | VKTX | -9.98 | 0.30 | 19.74 |
| 2026-06-08 | VKTX | -9.98 | 0.32 | 19.74 |
| 2026-06-09 | VKTX | -9.98 | 0.32 | 19.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.37
Avg. EPS Est. Current Quarter
-1.21
Avg. EPS Est. Next Quarter
-1.1
Insider Transactions
-9.98
Institutional Transactions
0.32
Beta
0.72
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
19
Sentiment Score
7
Actual DrawDown %
70.6
Max Drawdown 5-Year %
-78.9
Target Price
94.29
P/E
Forward P/E
PEG
P/S
P/B
6.75
P/Free Cash Flow
EPS
-4.15
Average EPS Est. Cur. Y
-4.72
EPS Next Y. (Est.)
-4.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
-96.7
◆
VKTX
Healthcare
$29.23
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.2
Range 1M
20.6%
Sup Dist
2.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-49%
EPS NY
-0.4%
52W%
30.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+222.6% upside
Upside
+222.6%
Quality
6
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 59
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX
Latest News
—
Caricamento notizie per VKTX…
stock quote shares VKTX – Viking Therapeutics Inc. Stock Price stock today
news today VKTX – Viking Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading